Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer

NCT02460367 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

16

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of enrollment and changing landscape of standard of care.

Conditions

Non-small Cell Lung Cancer
Progression of Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Recurrent

Interventions

DRUG: Docetaxel
BIOLOGICAL: Tergenpumatucel-L
DRUG: Indoximod

Sponsor

NewLink Genetics Corporation